Canaccord lowered the firm’s price target on AtriCure to $45 from $79 and keeps a Buy rating on the shares. The firm believes their thesis remains strong as product iterations in 2025/2026 and breakeven profitability via operating leverage are on the horizon.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATRC:
